Arrhythmogenic Cardiomyopathy: Towards Genotype Based Diagnoses and Management

Steven A. Muller,Giorgia Bertoli,Jianan Wang,Alessio Gasperetti,Moniek G. P. J. Cox,Hugh Calkins,Anneline S. J. M. te Riele,Daniel P. Judge,Mario Delmar,Richard N. W. Hauer,Gerard J. J. Boink,Marina Cerrone,J. Peter van Tintelen,Cynthia A. James

DOI: https://doi.org/10.1111/jce.16519

IF: 2.7

2024-12-04

Journal of Cardiovascular Electrophysiology

Abstract:To improve arrhythmogenic cardiomyopathy (ACM) patient care four pillars of ACM research are necessary. The first pillar to improve ACM is cohort studies in which the genotype‐specific natural history of disease is described, and subsequently genotype‐specific risk calculators can be developed, such as the DSP and PLN risk calculators. The second pillar is the basic and translational studies in which cellular pathways are described and potential genotype‐specific drug targets to slow progression or lower the risk of VA identified, such as flecainide in PKP2‐associated ARVC patients. Third, preclinical gene studies can improve ACM patient care to determine which vector has the optimal effect in which specific gene for gene therapy. The efficacy of gene therapy can subsequently be tested to hopefully improve or even cure ACM in clinical trials. Arrhythmogenic cardiomyopathy (ACM) is a genetically heterogeneous inherited cardiomyopathy with an estimated prevalence of 1:5000–10 000 that predisposes patients to life‐threatening ventricular arrhythmias (VA) and sudden cardiac death (SCD). ACM diagnostic criteria and risk prediction models, particularly for arrhythmogenic right ventricular cardiomyopathy (ARVC), the most common form of ACM, are typically genotype‐agnostic, but numerous studies have established clinically meaningful genotype‐phenotype associations. Early signs of ACM onset differ by genotype indicating the need for genotype‐specific diagnostic criteria and family screening paradigms. Likewise, risk factors for SCD vary by genetic subtype, indicating that genotype‐specific guidelines for management are also warranted. Of particular importance, genotype‐specific therapeutic approaches are being developed. Results from a randomized controlled trial for flecainide use in ARVC patients are currently pending. Research in a plakophilin‐2‐deficient mouse model suggests this antiarrhythmic drug may be particularly useful for patients with likely pathogenic or pathogenic (LP/P) PKP2 variants. Additionally, the first gene therapy clinical trials in ARVC patients harboring LP/P PKP2 variants are currently underway. This review aims to provide clinicians caring for ACM patients with an up‐to‐date overview of the current literature in genotype‐specific natural history of disease and management of ACM patients and describe scientific advances that have led to upcoming clinical trials.

cardiac & cardiovascular systems